Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MAX | P61244 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646471 | 0.89 | MEN1 (0.54) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL30061165 | 0.89 | MEN1 (0.54) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL7552860 | 0.89 | MEN1 (0.53) | POLBCYP19A1MEN1KMT2ANPC1 | |
| SCHEMBL1039049 | 0.87 | POLB (0.44) | POLBCYP19A1MEN1KMT2ANPC1 | |
| SCHEMBL12734031 | 0.87 | MEN1 (0.50) | POLBCYP19A1MEN1KMT2ANPC1 | |
| SCHEMBL27581338 | 0.86 | MEN1 (0.51) | POLBCYP19A1MEN1KMT2ANPC1 | |
| SCHEMBL1039005 | 0.86 | CYP19A1 (0.43) | POLBCYP19A1MEN1KMT2ANPC1 | |
| SCHEMBL5344847 | 0.84 | MEN1 (0.50) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL564577 | 0.84 | MEN1 (0.47) | POLBCYP19A1MEN1KMT2ANPC1 | |
| SCHEMBL1300529 | 0.83 | MEN1 (0.49) | POLBMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2276760-A1 | FUSED RING COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | POLB 3992/4885CYP19A1 69/4885MEN1 3151/4885 |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | POLB 3867/4885CYP19A1 54/4885MEN1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.